Depression Labs and Next Steps: Tests, Diagnosis, and What to Do Now

Why Your Doctor Orders Lab Tests for Depression

Depression is a clinical diagnosis. No blood draw can confirm it. But a focused lab panel serves a different purpose: it identifies medical conditions that produce identical symptoms. Fatigue, weight changes, poor concentration, and low mood all overlap with thyroid disease, anemia, and metabolic disorders. Ruling these out first prevents months of misdirected treatment.

The Standard Depression Lab Panel

The American Psychiatric Association (APA) recommends baseline laboratory studies before initiating antidepressant therapy [1]. A typical workup includes:

• TSH (thyroid-stimulating hormone): Hypothyroidism causes fatigue, weight gain, cognitive slowing, and depressed mood. A 2004 meta-analysis in the Journal of Clinical Psychiatry found subclinical hypothyroidism in up to 15% of patients presenting with depression [2].
• Complete blood count (CBC): Iron-deficiency anemia produces fatigue and difficulty concentrating that patients often attribute to depression.
• Comprehensive metabolic panel (CMP): Screens liver function, kidney function, electrolytes, and glucose. Hypoglycemia and hepatic dysfunction both affect mood.
• Vitamin D (25-hydroxyvitamin D): A 2013 meta-analysis of 31,424 participants published in the British Journal of Psychiatry found that low vitamin D levels were associated with a significantly higher risk of depression (OR 1.31, 95% CI 1.0 to 1.71) [3].
• Vitamin B12 and folate: B12 deficiency causes neuropsychiatric symptoms including depression, irritability, and cognitive decline. Older adults and those on metformin or proton pump inhibitors carry elevated risk [4].
• Fasting glucose or HbA1c: Type 2 diabetes doubles the odds of comorbid depression, per a 2001 meta-analysis in Diabetes Care [5].

When Additional Tests Are Warranted

Your clinician may order cortisol testing if Cushing syndrome is suspected (truncal obesity, moon facies, striae). Testosterone levels are appropriate for men with concurrent low libido, erectile dysfunction, or unexplained fatigue. A urine drug screen may be indicated if substance use is a contributing factor. None of these are routine for every patient, but targeted ordering closes diagnostic gaps that a standard panel misses.

Medical Conditions That Mimic Depression

Treating a thyroid disorder with an SSRI will not fix the thyroid. This is why the differential diagnosis matters as much as the screening score.

Thyroid Disorders

Both hypothyroidism and hyperthyroidism produce mood symptoms. The Endocrine Society's 2012 clinical practice guideline recommends TSH measurement in all patients with new-onset depressive symptoms [6]. Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) is particularly easy to miss because symptoms develop gradually.

Anemia and Iron Deficiency

A 2020 population-based study in BMC Psychiatry involving 11,876 adults found that iron-deficiency anemia was independently associated with a 1.53-fold increased risk of depressive disorders [7]. Fatigue from anemia overlaps almost perfectly with depressive fatigue, making the CBC one of the most cost-effective tests in the workup.

Vitamin Deficiencies

B12 deficiency affects 6% of adults under 60 and nearly 20% of those over 60, according to the CDC's Second National Report on Biochemical Indicators [8]. Neuropsychiatric manifestations can appear before hematologic changes, meaning a normal CBC does not exclude B12 deficiency. Serum B12 and methylmalonic acid levels provide a clearer picture.

Other Mimics to Consider

Sleep apnea, chronic pain syndromes, early neurodegenerative disease, and medication side effects (beta-blockers, corticosteroids, certain anticonvulsants) all produce depressive-type symptoms. A careful medication reconciliation and sleep history are part of any thorough evaluation.

How Depression Is Diagnosed

Once labs return and medical causes are excluded (or addressed), the diagnostic process shifts to standardized psychiatric assessment. The two pillars are structured screening instruments and clinical interview based on DSM-5 criteria.

The PHQ-9 and Other Screening Tools

The Patient Health Questionnaire-9 (PHQ-9) is the most widely validated depression screener in primary care. A 2001 validation study in the Journal of General Internal Medicine (N=6,000) demonstrated 88% sensitivity and 88% specificity for major depressive disorder at a cutoff score of 10 [9]. Scores break down as follows:

| PHQ-9 Score | Severity | |------------|----------| | 0 to 4 | Minimal or none | | 5 to 9 | Mild | | 10 to 14 | Moderate | | 15 to 19 | Moderately severe | | 20 to 27 | Severe |

The U.S. Preventive Services Task Force (USPSTF) issued a 2016 recommendation (Grade B) that all adults be screened for depression in primary care settings with adequate systems in place for follow-up [10].

DSM-5 Diagnostic Criteria

A formal diagnosis of major depressive disorder (MDD) requires five or more of nine symptoms present during the same two-week period, with at least one being depressed mood or loss of interest (anhedonia). The nine criteria include depressed mood, anhedonia, significant weight or appetite change, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, worthlessness or excessive guilt, diminished concentration, and recurrent thoughts of death [11].

Dr. Maurizio Fava, psychiatrist-in-chief at Massachusetts General Hospital, has noted: "The PHQ-9 is a starting point, not an endpoint. A positive screen should always trigger a full clinical interview to confirm diagnosis, assess severity, and evaluate for comorbid conditions like anxiety or substance use disorders" [12].

What a Clinical Interview Covers

Beyond symptom counting, clinicians assess the timeline of onset, functional impairment (work, relationships, self-care), family psychiatric history, prior episodes, past treatment response, and current safety risk. This context determines whether the episode is mild, moderate, or severe, which directly shapes the treatment recommendation.

Causes of Depression: What the Evidence Shows

Depression does not have a single cause. The biopsychosocial model remains the most accepted framework for understanding why some people develop the condition and others do not.

Biological Factors

Heritability estimates from twin studies range from 31% to 42%, according to a large meta-analysis published in Nature Genetics [13]. First-degree relatives of people with MDD carry a two- to threefold higher risk. The monoamine hypothesis (serotonin, norepinephrine, dopamine deficiency) guided drug development for decades, but current understanding has moved beyond simple chemical imbalance models. Neuroplasticity, HPA axis dysregulation, neuroinflammation, and gut-brain axis signaling all play roles [14].

Psychological and Social Factors

Adverse childhood experiences (ACEs), chronic stress, social isolation, job loss, grief, and trauma all increase depression risk. The landmark ACE Study (N=17,337) conducted by the CDC and Kaiser Permanente found that individuals with four or more ACEs had a 4.6-fold increased risk of depression compared to those with none [15].

Hormonal Contributions

Peripartum depression affects approximately 1 in 7 women, per ACOG Committee Opinion No. 757 [16]. Testosterone deficiency in men is associated with increased depressive symptoms, with the Endocrine Society recommending evaluation of testosterone in men with depression and concurrent sexual dysfunction [17]. Perimenopause represents another window of elevated vulnerability due to fluctuating estradiol levels.

Treatment Options After Diagnosis

The APA's 2010 Practice Guideline for the Treatment of Major Depressive Disorder recommends that treatment selection be based on episode severity, patient preference, prior treatment history, and comorbidities [1].

Psychotherapy

Cognitive behavioral therapy (CBT) is the most studied psychotherapy for depression. A 2013 Cochrane review of 115 trials found CBT superior to waitlist, no treatment, and treatment-as-usual controls for reducing depressive symptoms [18]. Effect sizes were moderate. Behavioral activation, interpersonal therapy (IPT), and problem-solving therapy also have strong evidence bases.

For mild to moderate depression, psychotherapy alone may be sufficient. The NICE guideline (2022 update) recommends psychological intervention as first-line for less severe depression, reserving combined medication and therapy for moderate-to-severe episodes [19].

Antidepressant Medications

SSRIs (sertraline, escitalopram, fluoxetine, paroxetine, citalopram) are first-line pharmacotherapy. The STAR*D trial (N=4,041), the largest effectiveness study of antidepressant treatment, found that approximately 33% of patients achieved remission with the first SSRI trial (citalopram), with cumulative remission rates reaching 67% after up to four treatment steps [20].

The 2018 Cipriani network meta-analysis in The Lancet, covering 522 trials and 116,477 participants, found that all 21 antidepressants studied were more effective than placebo, with agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine showing the highest response rates. For tolerability, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine had the lowest dropout rates [21].

Dr. Andrea Cipriani, professor of psychiatry at the University of Oxford, stated in the accompanying commentary: "Antidepressants work for moderate-to-severe depression. The choice of which one should be based on expected side-effect profile, patient preference, and cost."

SNRIs and Other Second-Line Options

If an SSRI fails or is poorly tolerated, SNRIs (venlafaxine, duloxetine), bupropion, or mirtazapine are common second steps. Bupropion carries lower risk of sexual dysfunction and weight gain, making it a practical choice for patients who experienced those side effects on an SSRI.

Exercise as Adjunctive Treatment

A 2023 umbrella review of 97 systematic reviews published in the British Journal of Sports Medicine found that physical activity significantly reduces depression symptoms across populations, with an effect size comparable to psychotherapy and pharmacotherapy for mild-to-moderate depression [22]. Walking, resistance training, and yoga all showed benefit. The dose most consistently studied: 150 minutes per week of moderate-intensity activity.

Building a Next-Steps Plan

Knowing your options matters less than acting on them. Here is a practical sequence for moving from suspicion to treatment.

Step 1: Get the Lab Work Done

Request the standard panel: TSH, CBC, CMP, vitamin D, B12, and fasting glucose. Most primary care offices can order these during the same visit as your depression screening. Results typically return within 2 to 5 business days.

Step 2: Complete a PHQ-9

You can complete the PHQ-9 at your doctor's office or download it from validated sources. A score of 10 or higher warrants a full clinical evaluation. Bring the completed form to your appointment.

Step 3: Address Any Medical Findings

If labs reveal hypothyroidism, B12 deficiency, or anemia, treat those conditions first or concurrently. Mood symptoms caused by a medical condition often improve with targeted treatment. A study in Thyroid found that levothyroxine treatment of subclinical hypothyroidism reduced depressive symptoms in 57% of patients who met depression criteria at baseline [23].

Step 4: Choose a Treatment Modality

For mild depression (PHQ-9 of 5 to 9): start with structured psychotherapy (CBT or behavioral activation), regular exercise, and follow-up PHQ-9 in 4 to 6 weeks.

For moderate-to-severe depression (PHQ-9 of 10 or higher): combination therapy (an SSRI plus psychotherapy) offers the highest remission rates. The NIMH-funded TADS trial in adolescents and the Keller et al. Study in adults with chronic MDD both showed combination treatment superior to either modality alone [24].

Step 5: Monitor and Adjust

Antidepressants require 4 to 6 weeks at therapeutic dose before efficacy can be assessed. The APA recommends measurement-based care, repeating the PHQ-9 at each visit to track response quantitatively [1]. A drop of 50% or more in PHQ-9 score constitutes clinical response. Full remission is defined as a score <5.

When to Seek Emergency Help

Some situations cannot wait for a scheduled appointment. Active suicidal ideation (thoughts with a plan or intent), self-harm behavior, psychotic features (hallucinations, delusions), or inability to care for oneself require immediate evaluation. Call 988 (the Suicide and Crisis Lifeline) or go to the nearest emergency department.

The CDC reports that suicide is the 11th leading cause of death in the United States, with 49,449 deaths in 2022 [25]. Early identification and intervention reduce risk. If a PHQ-9 item 9 (thoughts of self-harm) scores 1 or higher, clinicians should conduct a structured safety assessment at that visit.

Patients discharged from psychiatric emergency settings should have a follow-up appointment scheduled within 72 hours. That single scheduling step reduces 90-day readmission rates by approximately 30%, according to data from the National Alliance on Mental Illness.